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Abstract
The magnocellular neurons (MCNs) in the hypothalamus selectively express either oxytocin (OXT) or vasopressin (AVP)
neuropeptide genes, a property that defines their phenotypes. Here we examine the molecular basis of this selectivity in the
OXT MCNs by stereotaxic microinjections of adeno-associated virus (AAV) vectors that contain various OXT gene promoter
deletion constructs using EGFP as the reporter into the rat supraoptic nucleus (SON). Two weeks following injection of the
AAVs, immunohistochemical assays of EGFP expression from these constructs were done to determine whether the EGFP
reporter co-localizes with either the OXT- or AVP-immunoreactivity in the MCNs. The results show that the key elements in
the OT gene promoter that regulate the cell-type specific expression the SON are located 2216 to 2100 bp upstream of the
transcription start site. We hypothesize that within this 116 bp domain a repressor exists that inhibits expression specifically
in AVP MCNs, thereby leading to the cell-type specific expression of the OXT gene only in the OXT MCNs.
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Introduction
It is widely accepted that cell-type specific gene expression
determines cell identity in the nervous system [1,2] and that specific
neuropeptide expression is a robust marker that can distinguish
between neuronal phenotypes [3,4]. The neurohypophysial peptide
hormones, oxytocin (OXT) and vasopressin (AVP), are well known for
their roles in the periphery to stimulate milk let-down during lactation
and induce uterine contractions during parturition, and to regulate
systemic salt and water balance, respectively [5,6,7]. In recent years,
however, these neuropeptides have been shown to be released within
the central nervous system and to also have important physiological
and behavioral functions [7,8,9,10,11]. The OXT and AVP
neuropeptides are predominantly synthesized in three populations of
magnocellular neurons (MCNs) in the hypothalamo-neurohyophysial
system (HNS) of the brain, consisting of the supraoptic, paraven-
tricular, and accessory nuclei. The rodent supraoptic nucleus (SON) is
unique in that it contains only one neuronal phenotype, the MCN,
which is primarily represented by two distinct MCN subtypes in
approximately equal numbers, that are distinguished by their
respective commitments to express either the OXT or the AVP gene
[12]. These selectively expressing MCNs account for about 97% of
the. MCN population in the SON, and ,3% of the MCNs have been
shown to coexpress both peptides [13,14,15,16].
The genes for the OXT and AVP peptides are very similar, in
that both contain 3 exons and 2 introns and are located on the
same chromosome. They are separated from each other by as little
as 3.5 kb in the mouse and 11 KB in the rat and are oriented in a
tail to tail fashion, and therefore are transcribed towards each
other from opposite strands of the DNA [6]. An unanswered,
central question in this field has been what mechanisms are
responsible for the highly selective regulation of the cell-type
specific expression of OXT and AVP genes in the MCNs of the
SON. In attempts to address this question, many molecular studies
on the regulation of the expression of these genes have been done
using heterologous cell lines to determine which cis-elements in the
OXT and AVP genes are responsible for the selective MCN
expression. (reviewed in Burbach et al [6]). The data obtained
from these models have been generally useful, but it is clear that
heterologous cell lines, because of their de-differentiated states, are
not appropriate models for the study of the cell-type specific
regulation of the highly differentiated in vivo phenotypes. One
experimental approach that investigators have used to address this
question of cell-type specific expression of the OXT and AVP
genes has been the use of transgenes containing various
combinations of the OXT and/or AVP gene sequences in
transgenic rodents [17]. The data from these studies identified a
region ,0.6 kbp upstream of OXT exon I as having all of the
necessary components for cell-type specific expression of the OXT
phenotype in the SON [18,19].
In this paper, we make use of a new experimental approach to
perform promoter deletion analysis in vivo, that is to use stereotaxic
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32085injections of viral vectors for gene transfer into the SON in order
to further dissect the cis-elements in the ,0.6 kbp domain
upstream of the OXT gene transcription start site that regulate
the cell-type specific expression. This in-vivo method uses AAV
vectors expressing OXT-promoter deletion constructs and utilizes
the enhanced green fluorescent protein (EGFP) as the reporter.
The AAV constructs are stereotaxically injected into the rat brain
above the SON and 2 weeks post injection the rats are sacrificed
and assayed by immunohistochemistry for co-localization of EGFP
expression within OXT or AVP MCNs. Using this method we
have been able to identify an approximately 116 bp region
upstream of the transcription start site (TSS) in the OXT gene
promoter which is responsible for conferring the selectivity of
OXT gene expression in the SON.
Materials and Methods
Animals
Adult male Spraque-Dawley rats were obtained from Charles
River Laboratories (Wilmington, MA) and maintained under
normal laboratory conditions (temperature: 21–23uC, 12 hour
light-dark cycles with lights on at 6:00 AM) with access to
unlimited food and drinking water. Rats were caged individually
following surgical procedures. All animal procedures using rats
were carried out in accordance with National Institutes of Health
(NIH) guidelines on the care and use of animals and an animal
study protocol approved by the National Institute of Neurological
Disorders and Stroke (NINDS) Animal Care and Use Committee.
Plasmid Constructs
The pFBGR plasmid shown in Fig. 1A (obtained from Dr.
Robert Kotin, NIH\NHLBI) was used to construct all the
AAVOXT plasmids. pFBGR contains the AAV inverted terminal
repeats, ITRs, flanking the CMV promoter and EGFP reporter.
Bacterial transposon Tn7 L and R attachment sites are located
outside of the ITRs allowing the constructs to be incorporated into
the bacmid bMON14272 (Life Technologies, Carlsbad, CA USA).
The CMV-EGFP expressing AAV used in Fig. 2 B–D was made
using pFBGR as the starting plasmid. The OXT promoter
constructs to be inserted in the AAV vector (Fig. 1B) were made by
digesting pFBGR with XbaI to remove the sequences in between
the ITRs and ligating the OXT constructs into the XbaI sites.
XbaI sites are directly internal to both ITR sequences in the
pFBGR plasmid. All OXT promoter inserts were made using
PCR primers, with XbaI sites at the 59ends, to amplify the
construct of interest out of the plasmid OXTIII.EGFP.IGR3.6
previously described in Fields et al [20]. The pFBOT563 construct
was made using p563F GCTCTAGAGCGTCTACACAGCAG-
GTTCTAATACAGA and p563R GCTCTAGAGCCATGCC-
CTCACTTCTGCCCATTACT primers to amplify a 3 kb band
out of the plasmid OXTIII.EGFP.IGR3.6. This band contains
563 bp of the OXT 59UTR, OXT exons I–III with EGFP
inserted at the end of the OXT coding sequence of exon III
followed by 768 bp of the sequence downstream of OT exon III.
The 3 kb band was ligated into pFBGR that was digested with
XbaI. pFBOT440, 325, 216 and 100 were made by using a
forward PCR primers (TCTAGATTTTATTTTAATTTGGT-
CTGTTAACTCTG, TCTAGAGCCCTATCCTGCCTTATT-
CTGAG, TCTAGAACCCCTTCCAGGCTGCTTC, and TCT-
AGACACCCAAGAGACCTTCTGTGACC respectively) to re-
duce the length of the OT 59UTR and a reverse primer, OTR,
(CGCTAAAGGTATTCCCAGAAAGTGG) that binds to exon
III of pFBOT563 downstream of a NotI site in pFBOT563 used in
pFBOT563 as a linker to clone in the EGFP reporter. All of the
440-100 forward primers have an Xba I site at 59 end of the
primer. The 440-100 PCR products were digested with XbaI and
NotI and then cloned into pFB563 digested with NotI and the
XbaI site upstream of the OXT 59 UTR(via partial digestion).
This gives plasmids with 563, 440, 325, 216, and 100 bp of the
OXT 59UTR as shown in figure 1B. The pFBOT50 construct was
made using PCR primers OT50F GATCGAGCTCTGCTC-
CACCATGGCAGTGCCA and OT50R GATCGGATCCC-
GGGCCGCAACTCCGA to PCR out a 1.8 kb band from
OXTIII.EGFP.IGR3.6. This band was digested with SacI and
BamHI and ligated into SacI BamHI digested pFBOT100 giving a
plasmid similar to pFBOT100 but with only 50 bp of the 59 UTR.
All of the above PCR reactions were done using the Expand High
Fidelity PCR System (Roche, Germany) according to the
manufacturers instructions with a thermal cycler program of
94uC 2 min16,9 4 uC 15 sec 55uC 30 sec 72uC 1.5 min 106,
94uC 15 sec 55uC 30 sec 72uC 1.5 min plus 5 sec per cycle 256,
72uC 7 min 16.. All of the OXT-promoter deletion constructs
made for this study are shown in Fig. 1B.
Baculovirus and AAV construction
We used a recombinant Baculovirus (rBV) method that
employed insect cells for the production of AAVs which results
in an increased AAV production/transfected cell as compared to
the method using 293T cells [21]. rBVs were made as precursors
to AAV production in Sf9 insect cells using the Bac-to-Bac
Baculovirus Expression System, (Life Technologies). In order to
calculate accurate rBV ratios and Multiplicity of Infections (MOIs)
during the production of the AAVs, rBV titers were determined by
QPCR using a procedure modified from Lo et. al [22]. In this
method we used dilutions of intact rBVs as the template for QPCR
along with primers targeting the BV genome. Primers were
designed using the MacVector 7.0 program (MacVector, NC,
USA) and the Autographa californica multicapsid nucleopolyhedro-
virus DNA sequence (Accession# NC_001623). The primer
sequences used were B.V.109103–109124 59- ATGAAGCA-
CAGTGTCCACGGTC -39 and B.V. 109286-109264 59- GG-
TGAAGCGGCAGAATAACAATC -39 which amplify a 184 bp
amplicon from the viral envelope glycoprotein. The QPCR
reaction was performed in a Smart Cycler RT-PCR system
(Cepheid, CA, USA). The reactions were done using Real-Time
SYBR Green PCR master mix (SA Biosciences, MD, USA)
according to the manufacturer’s protocol with 1 ul of diluted
template (1:1000 or 1:10,000) added. The run profile was 95uC for
15 min 16,9 5 uC for 15 sec, 60uC for 30 sec, 72uC for 30 sec
406, followed by a 60uC–95uC melt curve. To generate a
standard curve for rBV tittering, DNA was isolated from rBV Bac-
RepCap6 (a gift from Dr. Robert Kotin, NIH\NHLBI) according
to the method of O’Reilly et al [23], and serial dilutions of the rBV
Bac-RepCap6 DNA were used as control template. Titers for all
newly manufactured rBV stocks were determined from this
standard curve.
In preliminary experiments, we found that of all the serotypes
tested (AAV2, AAV5, AAV6, AAV8, and AAV9) the AAV 5 and 6
serotypes were the most efficient in transducing the MCNs in the
SON. A rBV containing the AAV2 rep genes and the AAV6
capsid genes, Bac-RepCap6, which produces a serotype 6 AAV
was used for the AAV packaging reactions [24] rBVs containing
the OXT constructs shown in Fig. 1B were combined with the
Bac-RepCap6 rBV at a ratio of 3:1 and used to infect 200 ml of
Sf9 cells at density of 2610
6 cells/ml in suspension culture at a
MOI of 3 according to the method of Negrete et al [25]. Cells
were incubated for 3–4 days at 27uC while shaking at 115 rpm
until lysis-induced mortality reached at least 50% as measured by
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harvested by centrifugation at an RCF of 2000 g for 10 min and
the supernatant was saved. The cell pellet was resuspended into
10 ml of sterile PBS, and the cells subjected to three freeze/thaw
cycles and centrifuged again at 2000 g for 10 min. The
supernatant from this spin was combined with the supernatant
from the first spin. MgCl2 was added to a final concentration of
2 mM and the mixture incubated at 37uC for 30 min with 20 U/
ml benzonase (Sigma). After this incubation, PEG -8000 (Sigma,
St. Louis,MO) was added to a final concentration of 2% and the
mixture incubated over night at 4uC. The solution was centrifuged
at RFC 4000 g for 30 minutes to pellet the viral particles. The
supernatant was then discarded and the viral pellet re-suspended
into 12 ml of CsCl with a refractive index of 1.372. Recombinant
AAV was purified through a CsCl gradient by centrifuging at
38,000 rpm in a SW Ti-41 rotor (Beckman Coulter, Brea, CA) for
48 hrs. Fractions with a refractive index between 1.378-1.368 were
pooled and concentrated, while exchanging the buffer to 2 mM
MgCl2 in PBS, using a microcon YM-100 spin filter (Millipore,
MA).
QPCR was performed on the purified and concentrated AAVs
to determine their titers. The AAV titer was determined by
comparison with a standard curve made using pFBOT100 plasmid
DNA and used the following primers: EGFP F-ACCCTCGTG-
ACCACCCTGAC and EGFP R-ACCTTGATGCCGTTCT-
TCTGC which amplify a 130 bp fragment of the EGFP gene.
PCR conditions were the same as above for the rBV titers. AAV
titers are expressed as viral genome/ml (vg/ml). Viral titers used in
all experiments ranged between 1–7610
12 vg/ml as determined
by the above QPCR method
Stereotaxic targeting of AAVs into the rat SON
2–3 month old rats (270–425 g) were anesthetized with 5%
isoflurane (Baxter, Deerfield, IL) in a Stoelting gas anesthesia
adaptor for stereotaxic instruments (David Kopf Instruments,
Tujuna, CA) and placed into a stereotaxic apparatus (Stoelting,
Wood Dale, IL) in flat skull position. The scalp of the rat was
shaved and then sterilized with betadine, 30% betadine: 70%
ethanol, and lastly 70% ethanol. A rostral-caudal incision was
made to access the skull and two holes were drilled dorsal to the
Figure 1. Description of AAVs containing OXT promoter deletion constructs used in this study. A. Shows plasmid pFBGR, which was
used for making all constructs, this plasmid contains the AAV left and right inverted terminal repeats (ITR). B. shows diagrams of constructs made
containing sequences 568, 440, 325, 216, 100, and 50 bp upstream of the transcription start site of the OXT gene. These constructs contained all the
three exons and two introns in the OXT gene and with the EGFP reporter inserted at the end of the coding region of exon III, followed by 768 bp
downstream of OXT exon III. All constructs were placed into pFBGR between the XbaI sites after removal of the 2291 bp XbaI band (see panel A).
doi:10.1371/journal.pone.0032085.g001
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lateral on each side as determined using a stereotaxic atlas [26]. A
10 ul syringe with a 30 gauge needle was placed 28.8 to
29.0 mm ventral to bregma and 3 ul of the AAV viral constructs
was delivered to the SON area at a rate of 0.3 ul/min. Viral titers
used in the experiments ranged between 1–7610
12 vg/ml.
Following the injections, the holes were filled with bone wax
(Medline, IL) and the incision closed with interrupted sutures.
Ketoprofen (Fort Dodge Animal Health, IA) was administered
(5 mg/kg) after surgeries intraperitoneally. Fig. 2A shows a
coronal section of a rat brain in a diagram illustrating the method
used for injections.
Salt-loading of rats
In some experiments, systemic hyperosmotic stimulation of rats
was done. For this purpose, rats were salt-loaded by being given
2% NaCl in their drinking water for 1 week prior to being
sacrificed at two weeks post injection of the AAV constructs.
Immunohistochemistry (IHC)
Rats were killed 2 weeks after injection by overdose of isoflurane
anesthesia (Baxter, Deerfield, IL). Immediately upon death, rats
were perfused transcardially with 50–100 ml of phosphate-
buffered saline (PBS) followed by 200–250 ml of fixative solution
(4% paraformaldehyde in PBS, pH 7.4) at a perfusion rate of 5 ml
per min. Following the perfusion, the brains were removed and
cryoprotected with 5% sucrose, 0.9% saline for 4 hr to overnight
at 4uC, followed by 10% and 15% sucrose, 0.9% saline in a similar
manner and then stored at 280uC until use. Coronal sections
(16 um) were cut on a cryostat (Reichert-Jung 2800; Frigocut,
Heidelberg, Germany) and mounted onto colorfrost slides (12-550-
19, Fisher Scientific, Pittsburgh, PA). The slides were incubated in
fixative solution for 5 min then washed 36in PBS and incubated
in PBS containing 0.3% Triton-X for 5 min, washed 36in PBS
followed by incubation in PBS containing 10% NGS 0.6% triton
x-100 as blocking agent for 30 min and rinsed 36in PBS. Brain
sections were incubated with the mouse monoclonal antibodies
PS38 against OXT-neurophysin (OXT-NP), PS41 against AVP-
NP or PS 45 a pan-specific NP antibody at dilutions of 1:200 in
PBS with 1%BSA [27,28], or a polyclonal antibody against the
GFP protein, Ab-2090, (Abcam, Cambridge, UK) used at a
dilution of 1:1000 and incubated overnight at 4uC. After
incubation in primary antibodies, the slides were rinsed three
times for 5 min in PBS at room temperature. The AVP-IR and
OXT-IR slides were incubated in Alexa FlourH 594-conjugated
goat anti-mouse (Molecular Probes, Eugene, OR) secondary
antibody (1:500) to yield cytoplasmic red fluorescence. Alexa
FlourH 488(Molecular Probes) secondary antibody was used to
yield cytoplasmic green fluorescence in the experiments using
antibodies to EGFP. After immunohistochemistry the slides were
air dried in the dark then hydrated with a few drops of dH2O.
Cover slips were placed over them and images taken using an
Eclipse E400 fluorescent microscope (Nikon, Melville, NY)
equipped with a Exi Fast (QImaging, BC, Canada) CCD camera.
All the immunohistochemical data shown are representative of 3–5
independent experiments on rats. Measurements of the numbers
of either AVP- or OXT-identified MCNs that showed colocaliza-
tion of EGFP expressed from the AAV vectors injected into the
Figure 2. Efficacy of targeting both OXT and AVP magnocellular neurons (MCNs) in rat supraoptic nucleus (SON) by stereotaxic
injections of AAVs. The AAVs used were chimeric AAV6 serotypes with an AAV2 ITR and an AAV6 capsid (see Methods). A. Illustrates a rat brain
coronal section showing the placement of 30 gauge needles used for bilateral injections of AAVs to target the SON. Stereotaxic coordinates are
presented in Methods. Panels B–D show the results of injecting an AAV containing the CMV promoter fused to an EGFP reporter into the rat SON. B.
Illustrates EGFP fluorescence in the MCNs of the SON found two weeks after injection. C. shows OXT MCNs in the SON after staining with PS 38
antibody (an OXT MCN marker). D. Shows merged EGFP fluorescence and PS 38 staining. White Arrows in panels B–D show MCNs in the SON that
express EGFP co-localized with PS 38-immunoreactivity. Yellow arrow in panels B–D show MCNs that express EGFP which is not co-localized with PS
38-immunoreactivity, and hence are presumptive AVP MCNs. Abbreviations in A: cc, corpus callosum; LV, lateral ventricle; f, fornix; 3 V, third ventricle;
ic, internal capsule; PVN, paraventricular nucleus; SCN, suprachiasmatic nucleus; SON, supraoptic nucleus; OC, optic chiasm. Scale line in D is the same
for B and C.
doi:10.1371/journal.pone.0032085.g002
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matching of the EGFP stained and specific NP antibody stained
cells after double-label immunostaining.
Results
Efficacy of AAV vector-mediated gene transfer into OXT
and AVP MCNs in the rat SON
The evaluation of the cell-type specific expression of any gene
construct delivered into the SON by stereotaxic microinjection
(Fig. 2A) depends on the equivalent effectiveness of the AAV
vector used to transduce both the OXT and AVP MCNs by this
method. Figure S1 shows the intense labeling of the SON after
injection of an AAV containing a CMV-EGFP construct, and the
expression of EGFP in various non-MCNs surrounding the SON
where the virus could reach. Most important, we determined
whether such injections of AAV-6 containing CMV-EGFP
constructs into the SONs of rat brain would succeed in
transducing both populations of MCNs. It should be noted here
that the AAV-6 vector is not known to show neuronal specificity
with respect to its transduction efficacy [29,30,31], and hence
would be expected to transduce both MCN phenotypes equiva-
lently. Figs. 2B–D show the results of such an experiment in which
an AAV expressing the EGFP reporter under the control of a
CMV promoter was injected into the SON. Fig. 2B shows that two
weeks after injection the EGFP green fluorescence fills all the
MCNs in the SON, thus showing that this injection procedure
effectively transduces all of the MCNs in the SON. Fig. 2C
identifies the OXT MCNs in the same section stained red using
the PS38 antibody (the OXT-MCN marker). Fig. 2D shows a
merge of the images in fig. 2B and 2C. The white arrows in
Fig. 2B–D depict the oxytocin cells in the SON that clearly
coexpress EGFP, and the yellow arrows show EGFP expression in
cells that clearly do not express oxytocin, and are presumed to
represent the vasopressin MCNs, since OXT and AVP MCNs are
the only neuronal phenotypes found in the SON [12]. In a
separate set of experiments we injected the AAV-CMV-EGFP
constructs into the SON and determined the efficiency of the
AAV-6 to transduce all the MCNs in the SON by comparing the
MCNs expressing EGFP to MCNs that were double labeled with
the pan-specific neurophysin monoclonal antibody, PS 45, that
immunostains all the MCNs in the SON (see Fig. S2). After
evaluating 2,499 EGFP labeled cells in 9 injected SONs from 5
rats, we found that the EGFP expressing cells represented
69.1%629.5 (SD) of the total MCNs in the injected SON, and
of these 97.7%64.8 (SD) were double labeled by PS 45.
Therefore, we conclude that the efficiency of transduction with a
CMV promoter is about 69% and that both the OXT and AVP
MCN phenotypes are transduced by the AAV vector that is
stereotaxically injected in this manner (see Fig. S2).
Validation of the use of AAV gene transfer for evaluating
cell-type specific gene expression in the SON in vivo
Given the above demonstration that both OXT and AVP
MCNs in the SON are effectively transduced by the injected AAV
vector, we then tested an AAV that contained 563 bp of the OXT
promoter followed by the complete OXT gene with the EGFP
reporter placed at the end of the exon III coding region and
included 768 bp of the untranslated region downstream of exon
III (see p563 in Fig. 1B). Since this 563 bp OXT promoter had
previously been shown to produce cell-type specific expression of a
reporter in both transgenic mice [18] and in organotypic culture
[20] experiments, this AAV also served as a positive control for our
strategy to use AAV as a means to study the ability of various
promoter deletions to produce cell-type specific expression in the
MCNs of the SON in vivo. Fig. 3 shows the EGFP expression
Figure 3. Specificity of EGFP expression from the p563 AAV construct. Immunohistochemistrywas performed two weeks after injectionofthe
AAVs into the rat SON. Brain sections in A and D show EGFPfluorescence, in B, PS38 antibody staining, in C, merged EGFPfluorescence and PS38 staining, in
E,PS41antibodystaining,andinF,mergedEGFPfluorescenceandPS41staining.NotethatwhiletheEGFPisabundantlyexpressedintheOXTMCNs(panel
C), there is virtually no expression of the EGFP in the AVP MCNs (panel F). Abbreviations: OC, optic chiasm. Scale line in F is the same for all panels.
doi:10.1371/journal.pone.0032085.g003
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injecting this AAV into to the SON. In preliminary experiments
we determined that waiting two weeks after injection of the AAVs
was sufficient time to clearly observe the expressed EGFP in the
SON by immunofluorescent IHC (data not shown), Consequently,
unless otherwise stated, we routinely determined expression of the
EGFP reporter by immunofluorescence assays two weeks post
injection.
Figs. 3A–C illustrate a brain section with the EGFP fluorescence
shown in panel A, PS 38 antibody (OXT cell marker) staining in
panel B, and the merge in panel C. The yellow cells in the merged
view in panel C show that the EGFP expression is clearly
occurring in many OXT MCNs in the SON. However, there are
also green cells that appear to not to colocalize with the OXT
marker. This apparent lack of colocalization is due to the fact that
cells that have more intense green fluorescence than their
colocalized red fluorescence appear green in these unmanipulated
photographs. Therefore, it is difficult to illustrate the full extent of
colocalization by looking for exclusively yellow and no green cells
in these untouched photographs. However, the lack of colocaliza-
tion of the EGFP and the red AVP specific MCN marker in these
photographs, which is not influenced by this photographic artifact,
provides a more definitive test of cell-type specific gene expression.
Such a test is illustrated in Figs. 3D–F which shows another brain
section from the same rat SON with the green fluorescence in
panel D, and the PS 41 antibody (AVP cell marker) staining red in
panel E, and the merge is shown in panel F. In this case, the
merged view in panel F shows that the green fluorescence (EGFP
expression) is clearly occurring in MCNs that do not express the
AVP marker in red (presumably these are OXT MCNs). In order
to get a quantitative assessment of these colocalizations, in separate
experiments we injected the p563 OXT-promoter-EGFP AAV
into the SON and double label immunostained with either PS 38,
an OXT–specific or PS 41 an AVP-specific neurophysin antibody.
We then systematically evaluated the EGFP expressing cells in the
SON and compared them to their colocalized PS-38 or PS41
immunoreactivities as described in Methods. The results showed
that of 938 EGFP labeled cells evaluated in 6 injected SONs from
4 rats, we found that the EGFP was 95.0%63.3 (SD) colocalized
in identified (PS 38-ir) OXT MCNs, whereas of 1898 EGFP
labeled MCNs counted in 6 SONs from 4 rats, we found that the
EGFP expressing cells were only 3.7%62.2 (SD) colocalized in
identified (PS 41-ir) AVP MCNs. These quantitative data clearly
correspond to our conclusions about specificity which were drawn
from our interpretations of the images shown in Figure 3. The data
in Fig. 3D–F are also consistent with the well known observation
that OXT MCNs in the SON are located dorsal to the AVP
MCNs at this anatomical level of the nucleus. Therefore, we
conclude that there is virtually no expression of the p563 OXT
promoter construct in the AVP MCNs in the SON, a finding
consistent with our previous transgenic mouse data [18]. Also
similar to the transgenic findings, the p563 OXT promoter
construct shown in Fig. 1 did not cause ectopic expression, for
example it did not produce EGFP expression when injected into
cortex (data not shown).
Promoter deletion analysis of cell-type specific OXT gene
expression in the SON
In order to determine the locations of the regulatory elements in
the OXT gene that are responsible for its cell specific expression,
we injected AAVs that contained the six promoter deletion
constructs illustrated in Fig. 1B into rat SONs. These started with
the 563 bp construct discussed above and were systematically
decreased in length to 250 bp upstream of the TSS (Fig. 1). Fig. 4
summarizes the results of these experiments. The merged views
shown in this figure compares the cell locations of EGFP
fluorescence to AVP-neurophysin (PS 41) immunoreactivity which
represents the definitive test of specificity, and clearly show that
the EGFP expression is excluded from the AVP MCNs for all of
the constructs, except for the p100 and p50 constructs where the
EGFP is expressed in both AVP and OXT MCNs. From these
data we conclude that the cell-type specific regulatory element in
the OXT promoter is located between 2100 and 2216 bp
upstream of the transcription start site in the OXT gene, and
suggests that this domain most likely contains a repressor element
in the OXT promoter that suppresses OXT gene expression
specifically in the AVP MCNs. The data in Fig. 4 also shows that
there are small, unidentified neurons dorsal to the the SON which
appear to express EGFP from the p50 to p216 constructs, but
these small neurons do not express significant EGFP from the
p325 to p563 promoter constructs. Therefore, we propose that
there is another repressor element between 2216 bp to 2325 bp
upstream of the transcription start site in the OXT gene that
specifically prevents expression in these unidentified dorsal
neurons.
Figure 4. Analysis of the specificity of expression of EGFP from
AAVs containing various promoter deletion constructs (shown
in Fig. 1B) two weeks after their injection into rat SONs. The
specific promoter lengths that were injected into the SONs in each of
the experiments is shown in the lower left of the panels. Immunohis-
tochemical analyses show that each of the oxytocin promoter AAV
constructs was selectively expressed in oxytocin cells. Each panel
illustrates merged images of AVP-neurophysin (PS 41) immunoreactivity
shown as red, and the EGFF expression shown as green. Note that while
the EGFP is clearly not expressed in the AVP MCNs in panels A–D where
the promoter constructs contain 216 bp or more of the upstream
region, the p100 construct (panel E) and p50 construct (Panel F) shows
EGFP expression in both OXT. Hence the key elements regulating of the
selectivity of OXT gene expression must reside between in the 2216 to
2100 bp domain in the promoter. Abbreviations: OC, optic chiasm. The
100 mm scale line in lower right is the same for all panels.
doi:10.1371/journal.pone.0032085.g004
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promoter constructs shown in Fig. 1 all contained the intron and
exon sequences in the OXT gene. In order to determine whether
these regions were involved in the regulation of cell-type specific
gene expression in the SON, we injected an AAV vector that had
563 bp of the OXT promoter followed by exon 1 with the EGFP
reporter placed at the end of the exon 1 followed by 768 bp of the
untranslated region downstream of exon 3 (see the pOTI construct
shown in Fig. 5). The results of injecting this construct into the
SON are shown in Fig. 5A–C. Panel 5A shows the EGPF
fluorescence alone, panel 5B shows the merge of the green EGFP
fluorescence with the red PS38 (OXT) antibody stain, and panel
5C shows the merge of the EGFP fluorescence with the red PS41
(AVP) antibody stain. From these data we can see that the
expression of EGFP is not found in the AVP cells of the rat SON
indicating that removal of both introns and exon 2 and 3 do not
alter the cell-type specific expression properties of the OXT
promoter in the SON. In this regard, it has recently been shown
that the removal of all of the exons, introns, and the 768 bp of the
untranslated region downstream of exon 3 from a 2.6 kbp OXT
promoter fused directly to EGFP and inserted into an AAV which
was then injected into the SON, similarly showed that the EGFP
expression was OXT cell-type specific [32].
It is noteworthy that the fluorescence shown in Fig. 4 for the
p216, p100 and p50AAVs required amplification by EGFP
antibody staining to be adequately visualized, whereas the
p325bp to 563 bp AAVs did not require amplification. We
interpret this to be due to lower levels of expression in the
promoter regions that are 2216 bp or less. This view is reinforced
by the data shown for the controls in Fig. 6 whereas the intrinsic
fluorescence from the p440 and p563 AAVs were sufficiently
robust to be clearly observed without immunohistochemical
amplification. In contrast, the shorter deletion constructs were
not visible in these normosmotic rats without IHC amplification.
For this reason we suggest there may be an enhancer located
2216 to 2440 bp upstream of the OXT transcription start site.
Search for a putative osmotically regulated cis- element
in the OXT gene
The expression of the oxytocin gene in rat MCNs is known to be
dramatically regulated by changes in chronic, systemic osmolality
[6,33], and we were interested in determining if we could use our
promoter constructs to locate an element in the OXT gene
promoter that is associated hyperosmotic upregulation of OXT
gene expression in the SON. In this experiment, we used a
standard salt-loading approach to produce chronic hyperosmolal-
ity in rats (see Methods). In these experiments, the AAVs were
injected in the SON a week before the salt loading procedure
began and the rats were salt-loaded by the addition of 2% NaCl in
their drinking water at the beginning of the second week prior to
being sacrificed. Control animals were given normal water to
drink for the entire two weeks following the AAV injection. Fig. 6
shows the results of control versus salt loading on OXT gene
expression using the p50, p100, p440 and p563 series of OXT
promoter constructs. The left column shows EGFP fluorescence in
the SON of control normosmolar rats. The right column shows
EGFP fluorescence in the salt loaded, hyperosmotic rats. These
data show that the EGFP expression levels increase in the SONs of
all of the salt loaded rats as compared to the SONs of control rats.
This suggests that the putative element(s) affected by hyperosmotic
conditions are found within the first 50 bp of the OXT promoter
region or possibly further downstream in the gene. In this regard,
experiments by Knobloch et al, [32] have shown that neither the
introns nor exons in the OXT gene were necessary for the
osmotically induced increase in OXT gene expression. In view of
these data, we suggest that the osmotic regulation of the Oxt gene
is occurring within or below the 250 bp upstream region of the
OXT TSS in the core promoter.
Discussion
In this paper we examine an important aspect of the molecular
mechanisms that regulate cell-type specific OXT gene expression
Figure 5. Removal of exons 2 and 3, and both introns does not alter the specificity of expression properties of the OXT promoter.
An AAV was made containing the p563 OXT promoter- EGFP reporter construct (pOTI) shown at the bottom of the figure. The construct contains
568 bp of the OXT upstream promoter region followed by OXT exon I with the EGFP reporter gene fused to the end of exon I followed by 768 bp of
the region downstream of OXT exon III. The pOXTI AAV was injected into the SON of a salt loaded rat. A. shows EGFP Fluorescence, B. shows a merge
of EGFP fluorescence and OXT antibody staining in the same section, C. shows EGFP fluorescence and AVP-NP antibody staining in a different section
from the same rat SON. OC=optic chiasm. The scale line in A is the same for B and C.
doi:10.1371/journal.pone.0032085.g005
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element domains in the OXT gene promoter are responsible for its
cell-type specific regulation. Since there are no homologous cell
lines available that can serve as appropriate experimental
surrogates for the OXT-expressing MCNs found in vivo, we and
other investigators have previously addressed this issue by using
various experimental models that allow for studies of the
differentiated OXT MCNs themselves. Previous studies using
transgenic mice, have shown that transgenes containing ,600 bp
of the OXT gene promoter region upstream of the transcription
start site (TSS) and the entire intergenic region (3.6 kbp down-
stream of exon III) could reliably produce robust expression from
this construct only in the OXT MCNs, and none at all in the AVP
MCNs [18,19]. Subsequent studies conducted in vitro, using
biolistic transfection of the MCNs in organotypic cultures of
hypothalamus, showed that 554 bp upstream of the TSS in the
OXT gene was sufficient to produce expression in the OXT
MCNs [20]. For this reason we chose to start our deletions at
2563 bp upstream of the transcription start site.
The above biolistic experiments were primary directed at testing
whether downstream elements, i.e., in the intergenic region (the
IGR) were necessary for the cell-type specific expression of the
OXT and AVP genes in the hypothalamic cultures, as was
predicted by the ‘‘IGR hypothesis’’ [34,35]. In the Fields et al [20]
paper we reported that a 432 bp region downstream of exon III in
the OXT gene was necessary for the expression of the OXT gene
in the hypothalamic slice culture, and that a 178 bp downstream
of exon III in the AVP gene was necessary to produce AVP gene
expression in the hypothalamic culture. However, further
experiments in our laboratory indicated that neither the 178 bp
Figure 6. Effects of systemic salt loading on the expression of EGFP in MCNs after injection of various OXT promoter deletion
constructs into the rat SON. After injection of the AAVs into the SONs, the control rats were given water to drink for two weeks, whereas the salt
loaded rats were were given water for one week, followed by a second week of access only to water containing 2% NaCl (see Methods). Panels show
EGFP fluorescence in SONs of control (left column) and salt loaded (right column) rats for each of the p563, 440 bp, p100, and p50 OXT promoter-
containing AAVs. Control and salt loaded image capture times are identical for each construct. Note that for each deletion construct the SONs fom
salt loaded rats express much more EGFP than the control SONs, this is also the case for the pOXTI promoter construct. OC=optic chiasm. Scale bar in
bottom left panel is same for all panels.
doi:10.1371/journal.pone.0032085.g006
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elements responsible for the cell-type specific expression. The
178 bp and 432 bp domains appeared to contain similar motifs
(see Figure 8 in Fields et al, [20]) and we found that these
sequences could replace one another to produce the hypothalam-
ic-specific expression observed in the biolistics experiments (Fields
and Gainer, unpublished data). From the latter data, we
concluded contrary to the IGR hypothesis that the key cis-
elements that were responsible for the cell-type specific expression
of the OXT gene were not located downstream, but rather were
554 bp upstream of the transcription start site in the OXT gene.
However, since the biolistic studies reaffirmed that the 39 UTR in
the OXT gene was necessary for expression in the hypothalamic
organotypic cultures, we continued to use the 39 UTR in the OXT
gene in the construct in this study. While the previous studies using
transgenic or biolistic model systems provided valuable insights,
neither approach appeared to be sufficiently efficient or optimal
for the study of multiple promoter deletion constructs of the OXT
and AVP genes. For this reason, we decided to develop and use an
alternative approach, the AAV gene transfer method in vivo that is
used here and to focus our deletions in the 59 upstream region of
the OXT gene. In this regard, it should be noted here that
Knobloch et al [32] recently used the AAV approach to show that
all the introns and exons, as well as the 39 UTR (IGR) in the OXT
gene were not required for cell-type specific expression of a
2.0 kbp OXT gene promoter in the SON, thereby providing
experimental evidence against the IGR hypothesis. It is unclear at
present why the findings about the relevance of the 39 UTR on
OXT gene expression differ in experiments using biolistic
transfection in vitro versus AAV gene transfer in vivo, and this
issue should be examined further in the future.
Transgenic rodent models present several problems for promoter
deletion studies not the least of which is the excessive time and cost
of the animal husbandry associated with this approach. In addition,
the random insertion of the transgene often leads to artifacts such as
insertional mutations, and ectopic expression due to enhancer
trapping, and the latter problem is increased when the construct is
systematically shortened by the process of promoter deletion. The
biolistic transfection of organotypic cultures is limited by the very
low probability that the gold particles coated with plasmids that are
being randomly ‘‘shot’’ at the cultured slice explants will land in the
cell nucleus of an OXT-MCN without damaging the cell.
Furthermore, in the biolistic transfection method the particles do
notpenetrate more than 100 umintothe tissue,thereby makingthis
methodnotusefulfortransfectingthe ventrallylocated MCNsinthe
hypothalamus in vivo. Therefore, we turned to the highly efficient
recombinantAAV (AAV)method ofgenetransferinvivoforfurther
promoter deletion studies. This viral vector method had the
additional virtue of being able to be stereotaxically targeted by
microinjection to specific brain regions such as the SON, which had
large numbers of OXT- and AVP MCNs in approximately equal
numbers.
Viral vector methods are highly effective as a means to deliver
genes into the nervous system in vivo [36,37,38,39,40] and have
been used for gene transfer into hypothalamic neurons [40,41,42].
With respect to our study, we note that viral vector approaches
have also been successfully used to study gene promoter domains
that are involved in cell-type specific gene expression in vivo
[43,44,45,46,47]. The experiments described in this paper use
AAV vectors that contain promoter deletion constructs of the
OXT gene promoter fused to EGFP reporters to transduce
(transfect) neurons in the rat SON in vivo. AAV vectors have been
specifically shown to be more efficient than lentiviral vectors in
transducing neurons in the forebrain [48,49].
After stereotaxic injection of the AAVs into rat SONs, we allow
two weeks for expression of the EGFP, then perfuse fix the rat
brains, and perform IHC on cryostat sections of the hypothalamus
to assay the expression of the EGFP in either the OXT- or AVP
MCNs. Injections of AAVs containing 568 bp of the DNA
sequence upstream of the transcription start site (TSS) in the OXT
gene are able to produce robust expression selectively in OXT-
but not in the AVP –MCNs (Fig. 3). This was similar to the
transgene which was shown in previous transgenic studies to
produce cell-type specific expression in the MCNs [18]. Further
experiments showed that AAV vectors containing 440 bp, 325 bp
and 216 bp (but not 50 or 100 bp) upstream sequences of the
OXT gene promoter can all support cell-type specific OXT gene
expression in OXT MCNs and not in AVP MCNs (Fig. 4). It is
noteworthy that the fluorescence shown in Fig. 4 for the p216,
p100 and p50AAVs required amplification by EGFP antibody
staining due to their lower levels of expression, whereas the
intrinsic fluorescence from the p325 to p563 AAVs was sufficiently
robust to be clearly observed without immunohistochemical
amplification. For this reason we suggest there may be an
enhancer located greater than 216 bases upstream of the OXT
transcription start site. Fig. 4 also shows that the AAV containing
the 250 bp and 2100 bp upstream regions can produce EGFP
expression in the SON, but non-selectively in the OXT-and AVP-
MCNs, as might be expected of a ‘‘core promoter’’ region. Finally,
we show in Fig. 5 that introns 1 and 2 and exons 2 and 3 in the
OXT gene are not needed for cell-type specific expression in OXT
MCNs. These findings further suggest that the AAV vector in vivo
approach used here provide an effective general alternative to
conventional transgenic approaches for the study of gene
expression driven by promoter deletion constructs in the rat SON.
One surprising finding in this study is that the mechanism of the
well-studied osmotic regulation of the OXT gene [6] is present in
all of the deletion constructs studied, and appears to implicate the
core promoter in the osmoregulation of the oxytocin gene. The
images in Fig. 6 showing intrinsic fluorescence in SONs in control
and salt loaded rats were captured with the same exposure times so
that expression levels between dehydrated and salt loaded rats
could be directly compared. This figure shows that the putative
response elements associated with increased expression due to salt
loading are present in the p100 and p50 promoter regions and
thus are not linked with the cell-type specific expression domain
between 2216 to 2100. The increase in expression of the EGFP
in salt loaded rats is not accompanied by any changes in the
specificity of cell-type expression (unpublished data, Figs. 3 and
S3). One possibility is that the osmotic regulation resides near the
core promoter domain, possibly at the Pol II binding site. The
location of this regulatory element in the core promoter is
consistent with the global changes in gene expression found in the
SON in microarray studies [50,51], and the changes in nuclear
and somatic sizes of the MCNs in the SON [52,53] during
systemic, chronic osmotic perturbations. It is also possible that the
non-canonical TATA (Goldberg-Hogness) box sequence, known
to be present in the core promoters of the AVP and OXT genes
[54,55], might be involved in the osmotic regulation of the OXT
gene. While it is possible that the non-canonical TATA box could
be involved, we know of no paper in the literature that either
shows evidence for or that suggests this possibility for the OXT
gene. The only papers in the literature that address the osmotic
regulation issue focus only on the AVP gene, and these are
exclusively studies using heterologous cell lines (e.g, SCLC, HeLa,
and HEK293). They report osmotic regulatory sites in the AVP
gene that are located in the 59 flanking sequence between 21500
and 2532 bp upstream of the TSS [56,57], and are clearly
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only evidence that the non-canonical TATA box could be
involved in regulating the AVP gene has again been shown in
heterologous cell lines [58,59] and not in MCNs. Therefore,
whether the non-canonical TATA box is involved in the osmotic
regulation of the OXT and AVP genes remains completely
speculative. However, in this regard, it would be interesting to
know whether all the genes in the SON that have been shown in
microarray studies to be osmoregulated in vivo [50] all contain
non-canonical TATA boxes.
Based on data presented in this paper, we hypothesize that: 1)
there is a repressor element, (RE) in the 2216 to 2100 59
upstream region of the OXT gene that prevents its expression in
AVP MCNs, 2) that there is another potential RE in the 2325 to
2216 region upstream of the TSS in the OXT gene which
prevents expression in a non-MCN, unidentified dorsal neuron
population above the SON, and 3) that there is an enhancer in the
2216 bp to 2440 bp domain region upstream of the TSS in the
OXT gene that participates in the OXT MCN’s expression
(summarized in Fig. 7). In another series of experiments we
injected the AAVs from p563 to p100 (illustrated in Fig. 1) into the
rat cortex and found no detectable EGFP expression there (data
not shown). Given these results, we propose that there is another
repressor domain in the 2100 to 21 region in the OXT promoter
that prevents expression in extra-hypothalamic areas of the brain.
The most important finding in this paper with respect to
regulation of cell-type specific expression in the SON is that the
2216/2100 bp region in OXT gene promoter contains the key
elements that determine its cell-type specific expression in the
OXT MCNs in vivo, and this proposal is further informed by the
extensive reports of in vitro studies that have focused on this
promoter domain. Promoter deletion studies in the 1990s using a
variety of heterologous cell lines identified this region in the OXT
promoter as containing functional estrogen/retinoic acid receptor-
like transcription factor binding sites. Richard and Zingg [60,61]
using 59 deletion mutants of the human OXT gene that were
expressed in Neuro 2A cells identified a 2381 to +36 bp region in
the OXT promoter that overlapped with an estrogen response
element (ERE) motif between 2164 to 2152. Mutant constructs
containing this region increased four-fold in expression in response
to retinoic acid in cells that were co-transfected with a retinoic acid
receptor a, thus suggesting that this domain in the OXT gene
contained a retinoic acid receptor element (RARE). A similar
domain was reported as being present in the bovine OXT gene
promoter at 2160/2152 bp, which was characterized as having
an orphan chicken ovalbumin upstream promoter (COUP)-like
element [62,63] that bound a SF-1-like orphan receptor. Adan et
al. [64,65,66] reported the presence of a core domain at 172/
2148 in the rat gene promoter that increased OXT gene
expression in P19 cells in response to thyroid hormone (T3). These
authors subsequently referred to this domain as the Composite
Hormone Response Element (CHRE) since it could bind a variety
of classical and orphan nuclear hormone receptors (see Burbach,
[67], for a review of the CHRE concept), and Lopes da Silva and
Burbach [68], for a discussion of the diversity of nuclear hormone
receptor super family members found in brain. Most of the above
nuclear hormone receptors (NHRs) that were found to activate
OXT-promoter gene expression in heterologous cell lines, were
classical NHRs. However, Chu and Zingg [69] showed that a
mouse OXT gene promoter transfected into Neuro 2A is activated
by ROR a, a member of the ROR/RZR orphan receptor
subfamily, to produce a six-fold increase in transcription at two
sites (2160 bp and 180 bp) in the CHRE region.
While many studies identified NHRs that could activate OXT
gene expression, there are also reports that describe repressor
actions of NHRs in the same CHRE domain. The earliest
example of this was the demonstration of a negative retinoic acid
element (termed nRARE) at 2178/2158 bp in a rat OXT gene
promoter transfected into an African green monkey kidney cell
line [70]. Other examples, are the demonstration that SF-1
binding at the 2160 bp element in the bovine OXT promoter
inhibited the activation of OXT gene expression induced by
COUP-TF binding [71], and a report that estrogen, retinoic and,
or thyroid hormone stimulation of OXT gene expression in P19
cells was fully inhibited by COUP-TF-1 [72]. Along the same
lines, another group reported that COUP-TF II and Ear 2 act as
silencers of estrogen stimulated transcription of human OXT gene
expression in Neuro 2A cells [73]. Another NHR present in the
SON is estrogen receptor beta, and interestingly its expression is
normally greater in AVP MCNs than in OXT MCNs and is
inversely correlated with the level of expression of the neuropep-
tide genes [74]. This finding suggests a possibility that estrogen
receptor beta might play a role to repress OXT gene expression in
the AVP MCNs.
The above in vitro studies identified specific binding sites within
the 2216/2100 bp domain in the OXT gene promoter that we
have shown in our studies are responsible for the cell-type specific
expression of the OXT gene in MCNs in the SON in vivo. Since
the in vitro studies have shown that specific NHRs can act as
either activators or inhibitors of OXT gene expression, these data
are consistent with our hypothesis that elements in this 116 bp
domain could regulate the activation or repression of OXT gene
transcription in the OXT- or AVP MCNs, respectively, depending
on the specific NHRs being expressed in each of these cell-types.
In an effort, to identify the specific NHRs that are expressed in the
SON, Lopes de Silva and Burbach [75]used a polymerase chain
reaction/homology cloning strategy to identify NHRs that are
present in the microdissected SON. They found that five classical
receptors and four orphan receptors were expressed in the SON,
but only one of these, the thyroid hormone receptor-a (THRa)
was found by in situ hybridization histochemistry to be expressed
in the MCNs [75,76]. Unfortunately, there were no experiments
reported that provide information as to whether the THRa is
preferentially expressed in the OXT- or the AVP MCNs.
Figure 7. Diagram summarizing the cis-regulatory domains in
the oxytocin gene promoter as suggested by the data in this
study. The 250 bp and 2100 bp OXT promoter domains are sufficient
to produce expression of an EGFP reporter in both OXT and AVP MCNs
in the SON, and in a population of smaller neurons just dorsal to the
SON. The 2100 to 2216 bp domain appears to contain a repressor
element that inhibits expression specifically in AVP MCNs. The 2216 to
2325 domain appears to repress expression in an unidentified dorsal
neuron population above the SON, and the 2216 to 2440 bp domain
may have enhancer elements which are operative in the OXT MCNs.
doi:10.1371/journal.pone.0032085.g007
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dissect the 2216/100 bp domain in vivo, to determine whether
there is a selective OXT-versus AVP-MNC expression of THRa
and other candidate NHRs.
Supporting Information
Figure S1 Shows a low power view of a coronal section
of the rat hypothalamus after injection into the SON of
an AAV containing the pan-specific CMV promoter fused
to an EGFP reporter. Note that the SON shows intense EGFP
fluorescence and that areas dorsal and medial(towards the 3 V) also
show significant although less dense cellular fluorescence indicating the
wide area of potential transduction deriving from this AAV injection.
Dotted line shows dorsal boundary of the SON. Abbreviations: OC,
optic chiasm; 3 V, third ventricle. Scale line is 150 mm.
(TIF)
Figure S2 Illustrates the results from an experiment
where the EGFP fluorescence shown in the SON in A, two
weeks after injection of a CMV-EGFP-containing AAV
vector, is compared to the immunofluorescence ob-
served after immunostaining the same section with the
PS 45 antibody, which detects both AVP- and OXT-
associated neurophysins (in B), and therefore identifies
both the AVP- and OXT- MCNs in the SON. The merged
view is shown in C. Measurements of the numbers of MCNs in the
SON that colocalize the PS 45-ir with the EGFP fluorescence
forms the basis for the determination of the AAV efficiency of
transduction in the SON (see Methods and text). Abbreviations:
OC, optic chiasm. Scale line is 100 mm.
(TIF)
Figure S3 A and D show the detection of EGFP
immunofluorescence (using an antibody against EGFP)
in the SON after injection of a p563OXT-EGFP-contain-
ing AAV vector and with the use of the salt loading
paradigm (see Methods). The section in A was also
immunostained with the PS 41 (AVP-neurophysin-specific)
antibody shown in B, and the merge of A and B is shown in C.
Similarly, The section in D was also immunostained with the PS
38 (OXT-neurophysin-specific) antibody shown in E, and the
merge of D and E is shown in F. Note that the use of EGFP
antibody to amplify the EGFP detection and the use of salt loading
to increase the expression of the p563 construct (see Fig. 6) did not
alter its specificity of expression (compare these data with the data
in Fig. 3).Abbreviations: OC,optic chiasm. Scale line is 100 mm.
(TIF)
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